Results 111 to 120 of about 1,701 (232)

Histamine and migraine revisited: mechanisms and possible drug targets

The Journal of Headache and Pain, 2019
Objective To review the existing literature on histamine and migraine with a focus on the molecule, its receptors, its use in inducing migraine, and antihistamines in the treatment of migraine. Background Histamine has been known to cause a vascular type
Jacob Worm, Katrine Falkenberg, Jes Olesen   +2 more
doaj   +1 more source

504 Assessment of the Clinical Benefits of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy [PDF]

, 2021
Gerard Meskill, Craig W. Davis, Donna Zarycranski, Markiyan Doliba, Jean‐Charles Schwartz, Jeffrey M. Dayno   +5 more
openalex   +1 more source

The histamine H3 receptor: from discovery to clinical trials with pitolisant [PDF]

British Journal of Pharmacology, 2011
The third histamine receptor was discovered in 1983 by a traditional pharmacological approach, consisting of assessing the inhibitory effect of histamine on its own release from depolarized rat brain slices. The samein vitrotest was used to design, in 1987, the first highly selective and potent H3‐autoreceptor ligands, the antagonist thioperamide and ...
openaire   +2 more sources

Recent advances in treatment for narcolepsy

Therapeutic Advances in Neurological Disorders, 2019
Narcolepsy type 1 (NT1) is a chronic orphan disorder, caused by the selective and irreversible loss of hypocretin/orexin (ORX) neurons, by a probable autoimmune process.
Lucie Barateau, Yves Dauvilliers
doaj   +1 more source

Anticonvulsant and procognitive properties of Novel Histamine H3 Receptor Antagonists in male adult rats [PDF]

, 2016
To determine the potential of histamine H3 receptor (H3R) ligands as new antiepileptic and procognitive drugs, aromatic ether derivatives (1-12) belonging to the nonimidazole class of ligands, with high in-vitro binding affinity at human H3R, were tested
Saad, Ali Kassem
core   +1 more source

Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Excessive Daytime Sleepiness in Narcolepsy: A Network Meta-Analysis

Nature and Science of Sleep, 2023
Shuqin Zhan,1 Hui Ye,2 Ning Li,1 Yimeng Zhang,1 Yueyang Cheng,1 Yuanqing Wang,1,3 Shimin Hu,1 Yue Hou1 1Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, People’s Republic of China; 2Ignis Therapeutics (Shanghai ...
Zhan S, Ye H, Li N, Zhang Y, Cheng Y, Wang Y, Hu S, Hou Y   +7 more
doaj  

0768 Time Course Of Improvement In Excessive Daytime Sleepiness And Cataplexy During Treatment With Pitolisant In Patients With Narcolepsy [PDF]

, 2020
A. Roy, Craig W. Davis, Ben Vaughn, Jeffrey M. Dayno, Yves Dauvilliers, Jean‐Charles Schwartz   +5 more
openalex   +1 more source

First Report on Cationic Triphenylphosphonium Compounds as Mitochondriotropic H₃R Ligands with Antioxidant Properties

Antioxidants
Neurodegenerative diseases are a major public health problem due to the aging population and multifaceted pathology; therefore, the search for new therapeutic alternatives is of the utmost importance.
Tobias Werner, Tito Añazco, Paula Osses-Mendoza, Alejandro Castro-Álvarez, Cristian O. Salas, Raquel Bridi, Holger Stark, Christian Espinosa-Bustos   +7 more
doaj   +1 more source

REM sleep in narcolepsy [PDF]

Narcolepsy is mainly associated with excessive daytime sleepiness, but the characteristic feature is abnormal rapid eye movement (REM) sleep phenomena.
Dauvilliers, Yves, Siegel, Jerome M, Thorpy, Michael J   +2 more
core   +1 more source

Comorbidity of obstructive sleep apnea and narcolepsy: A challenging diagnosis and complex management

Sleep Medicine: X
Introduction: Narcolepsy and obstructive sleep apnea syndrome (OSA) are relevant causes of excessive daytime sleepiness (EDS); although different for etiopathogenesis and symptoms, differential diagnosis is sometimes difficult, and guidelines are lacking
Silvia Miano, Leila Kheirandish-Gozal, Marco De Pieri   +2 more
doaj   +1 more source